background: streptokinase is a potent activator of plasminogen to plasmin, the enzyme that can solubilize the fibrin network in blood clots. streptokinase is currently used in clinical medicine as a thrombolytic agent. it is naturally secreted by β-hemolytic streptococci. methods: to reach an efficient method of purification, an immunoaffinity chromatography method was developed that could puri...

objective(s): streptokinase (ska) is an antigenic protein which is secreted by streptococcus pyogenes. streptokinase induces inflammation by complement activation, which may play a role in post infectious diseases. in the present study, recombinant streptokinase from s. pyogenes was produced and showed that recombinant ska protein was recognized by infected human sera using western blot analysi...

T HE FEASIBILITY of producing dissolution of thrombi by enzymatic means has been demonstrated in experimental thrombi and pulmonary emboli in animals, in experimental venous thrombi in man6 and in patients with acute venous and arterial thromboembolic disease.7 8 Of the enzymes investigated, only the two plasminogen activators, streptokinase and urokinase, have proved acceptable as thrombolytic...

STUDY OBJECTIVE To investigate the effects of streptokinase and deoxyribonuclease (DNase) on the viscosity of pus to assess whether the DNase in the old preparation of streptokinase-streptodornase used intrapleurally to treat empyema was contributing to easier drainage of pus compared with purified streptokinase. DESIGN In vitro measurement of pus viscosity. PATIENTS Pus from three patients...

BACKGROUND AND OBJECTIVES Streptokinase is used clinically as an intravenous thrombolytic agent for the treatment of acute myocardial infarction and is commonly prepared from cultures of Streptococcus equisimilis strain H46A. The objective of the present study was the production of streptokinase from strain H46A and purification by chemical reduction method. MATERIALS AND METHODS The rate of ...

BACKGROUND A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat streptokinase therapy. Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous treatment with streptokinase...

the measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...

The risk of bleeding associated with intracoronary infusion of streptokinase in acute myocardial infarction was determined in a randomised controlled trial containing 302 patients under the age of 70. Intracoronary streptokinase infusion was given to 152 patients and 150 patients were treated conventionally. Bleeding was seen in 24 (16%) patients in the streptokinase group and in two of the con...

Streptokinase, an extracellular protein produced by Streptococci, is capable of activating the human fibrinolytic zymogen plasminogen. The rate of amidolytic activity of the plasminogen-streptokinase complex is greatly diminished by micromolar concentrations of ATP and heparin oligosaccharides. In addition, the plasminogen activator activity of the plasminogen-streptokinase complex is also inhi...

BACKGROUND AND PURPOSE Hemorrhagic transformation (HT) is the most critical complication of thrombolytics in clinical trials in acute stroke. The aim of this study was to determine the rates and the predictors of HT in the Multicenter Acute Stroke Trial-Europe (MAST-E) study. METHODS We performed a post hoc analysis of MAST-E data designed to assess the safety and efficacy of streptokinase ad...